ArticleFrontiers in immunology2025
Identification of key genes in membranous nephropathy and non-alcoholic fatty liver disease by bioinformatics and machine learning.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artificial Intelligence-Driven Food Safety: Decoding Gut Microbiota-Mediated Health Effects of Non-Microbial Contaminants.Foods (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic kidney disease (CKD) and non-alcoholic fatty liver disease (NAFLD) are closely associated. However, membranous nephropathy (MN), one of the causes of CKD, may contribute to NAFLD through abnormalities in lipid metabolism. Methods: 93 patients diagnosed with MN by renal biopsy and admitted to Henan Provincial People's Hospital between August 2021 and August 2022 were enrolled in this study. Patients were divided into two groups based on the presence or absence of NAFLD. Publicly available datasets related to NAFLD and MN were obtained from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) were identified, and weighted gene co-expression network analysis (WGCNA) was conducted to identify module genes. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed. A protein-protein interaction (PPI) network was constructed, and key genes associated with both diseases were identified using Cytoscape software and machine learning algorithms. The correlation between immune cell infiltration and the two diseases was evaluated using the CIBERSORT algorithm. Finally, the key gene expression was validated using external datasets and immunohistochemistry (IHC). Results: Compared with the non-NAFLD group, patients in the NAFLD group had significantly higher body weight, hemoglobin levels, triglycerides, and complement C3 and C4 levels. Conversely, IgG levels were significantly lower in the NAFLD group. A total of 211 shared DEGs were identified between MN and NAFLD, including 175 upregulated and 36 downregulated genes. Enrichment analysis indicated that these genes were primarily involved in immune and inflammatory responses. PPI network analysis identified seven hub genes: Conclusion: This study suggests that CSF1R is a shared molecular of MN and NAFLD, which may serve as a potential therapeutic target for patients affected by both diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.